Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fuji
Chinese Patent Office
Healthtrust
McKesson
Covington
Chubb
Express Scripts
Citi

Generated: September 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021882

« Back to Dashboard

NDA 021882 describes EXJADE, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the EXJADE profile page.

The generic ingredient in EXJADE is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 021882
Tradename:EXJADE
Applicant:Novartis
Ingredient:deferasirox
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021882
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882 NDA Novartis Pharmaceuticals Corporation 0078-0468 0078-0468-15 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0468-15)
EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882 NDA Novartis Pharmaceuticals Corporation 0078-0469 0078-0469-15 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0469-15)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, FOR SUSPENSION;ORALStrength125MG
Approval Date:Nov 2, 2005TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jan 23, 2020
Regulatory Exclusivity Use:TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
Patent:➤ Try a Free TrialPatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, FOR SUSPENSION;ORALStrength250MG
Approval Date:Nov 2, 2005TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jan 23, 2020
Regulatory Exclusivity Use:TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.

Expired US Patents for NDA 021882

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-001 Nov 2, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-003 Nov 2, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-002 Nov 2, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Daiichi Sankyo
Accenture
Deloitte
Dow
Baxter
Healthtrust
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.